X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (661) 661
animals (594) 594
spiro compounds - therapeutic use (567) 567
index medicus (532) 532
spiro compounds - pharmacology (482) 482
male (450) 450
female (303) 303
pharmacology & pharmacy (268) 268
mice (254) 254
rats (226) 226
spiro compounds - chemistry (224) 224
middle aged (180) 180
adult (177) 177
chemistry, medicinal (140) 140
dose-response relationship, drug (127) 127
spiro compounds - administration & dosage (126) 126
aged (125) 125
spiro compounds - adverse effects (122) 122
spiro compounds - chemical synthesis (99) 99
chemistry, multidisciplinary (97) 97
molecular structure (97) 97
biochemistry & molecular biology (93) 93
disease models, animal (89) 89
structure-activity relationship (89) 89
antineoplastic agents - therapeutic use (84) 84
cancer (83) 83
neurosciences (80) 80
spiro compounds (76) 76
rats, sprague-dawley (75) 75
analysis (74) 74
apoptosis (74) 74
indoles - pharmacology (74) 74
oncology (73) 73
article (72) 72
time factors (70) 70
treatment outcome (68) 68
cell line, tumor (64) 64
spiro compounds - pharmacokinetics (64) 64
antineoplastic agents - pharmacology (63) 63
administration, oral (62) 62
activation (60) 60
derivatives (60) 60
adolescent (58) 58
double-blind method (58) 58
clinical trials as topic (57) 57
apoptosis - drug effects (55) 55
chemistry, organic (55) 55
indoles - therapeutic use (55) 55
care and treatment (53) 53
rats, wistar (52) 52
drug design (51) 51
research (51) 51
pharmacology (50) 50
chemistry (49) 49
drug evaluation (46) 46
antidiuretic hormone receptor antagonists (45) 45
cell biology (45) 45
schizophrenia - drug therapy (44) 44
mice, inbred c57bl (43) 43
multidisciplinary sciences (43) 43
spiro compounds - metabolism (43) 43
cell proliferation - drug effects (42) 42
double-blind (42) 42
drug discovery (42) 42
organic chemistry (42) 42
models, molecular (41) 41
morpholines - therapeutic use (41) 41
drug therapy (40) 40
expression (40) 40
inhibitors (40) 40
spiro compounds - toxicity (40) 40
health aspects (39) 39
proteins (39) 39
biomedicine (37) 37
pharmacology/toxicology (37) 37
antineoplastic agents - adverse effects (36) 36
cell line (36) 36
discovery (36) 36
drugs (36) 36
microbiology (36) 36
drug evaluation, preclinical (35) 35
piperidines - therapeutic use (35) 35
chronic disease (34) 34
dogs (34) 34
drug therapy, combination (34) 34
enzyme inhibitors - pharmacology (34) 34
in-vitro (34) 34
in-vivo (34) 34
indoles - chemistry (34) 34
rat (34) 34
biology (33) 33
pyridines - pharmacology (33) 33
research article (33) 33
inflammation (32) 32
stereoisomerism (32) 32
young adult (32) 32
efficacy (31) 31
fluspirilene - therapeutic use (31) 31
neoplasms - drug therapy (31) 31
parasitology (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1066) 1066
Russian (39) 39
German (31) 31
Japanese (30) 30
French (17) 17
Italian (7) 7
Polish (5) 5
Spanish (4) 4
Chinese (2) 2
Czech (1) 1
Hungarian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 11/2017, Volume 65, Issue 10, pp. 1711 - 1720
Background. Administration of artemisinin-based combination therapy (ACT) to infant and young children can be challenging. A formulation with accurate dose and... 
dispersible tablet | arterolane maleate | P. falciparum | pediatric | INFECTIOUS DISEASES | ADULTS | MICROBIOLOGY | IMMUNOLOGY | COMBINATION | ANTIMALARIAL | CHILDREN | PHARMACOKINETICS | DIHYDROARTEMISININ-PIPERAQUINE | ARTESUNATE PLUS AMODIAQUINE | Quinolines - blood | Ethanolamines - adverse effects | Artemisinins - pharmacokinetics | Tablets | Humans | Fluorenes - therapeutic use | Antimalarials - blood | Child, Preschool | Infant | Male | Spiro Compounds - therapeutic use | Peroxides - therapeutic use | Spiro Compounds - adverse effects | Peroxides - pharmacokinetics | Peroxides - adverse effects | Quinolines - pharmacokinetics | Ethanolamines - pharmacokinetics | Malaria, Falciparum - mortality | Artemisinins - blood | Female | Fluorenes - adverse effects | Fluorenes - blood | Child | Antimalarials - adverse effects | Fluorenes - pharmacokinetics | Malaria, Falciparum - drug therapy | Antimalarials - pharmacokinetics | Heterocyclic Compounds, 1-Ring - pharmacokinetics | Africa | Antimalarials - therapeutic use | Spiro Compounds - pharmacokinetics | India | Ethanolamines - blood | Peroxides - blood | Artemisinins - therapeutic use | Spiro Compounds - blood | Heterocyclic Compounds, 1-Ring - adverse effects | Survival Analysis | Heterocyclic Compounds, 1-Ring - therapeutic use | Ethanolamines - therapeutic use | Quinolines - therapeutic use | Heterocyclic Compounds, 1-Ring - blood | Artemisinins - adverse effects | Drug Combinations | Quinolines - adverse effects
Journal Article
Neuropharmacology, ISSN 0028-3908, 08/2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | 5-HT1A RECEPTOR ANTAGONISTS | REUPTAKE INHIBITORS | DORSAL RAPHE | ADULT ZEBRAFISH | ELEVATED PLUS-MAZE | T-MAZE | NEUROSCIENCES | IN-VIVO | PHARMACOLOGY & PHARMACY | BRAIN | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4, p. e60933
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat... 
CANDIDATE | SQ109 | IDENTIFICATION | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | Pyrazoles - therapeutic use | Antitubercular Agents - chemistry | Humans | Drug Resistance, Bacterial | Spiro Compounds - therapeutic use | Tuberculosis - microbiology | Chromatography, Thin Layer | Mycobacterium tuberculosis - drug effects | Microbial Sensitivity Tests | Pyrazoles - chemistry | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Tuberculosis - drug therapy | Pyrazoles - pharmacokinetics | Spiro Compounds - chemistry | Antitubercular Agents - therapeutic use | Disease Models, Animal | Pyrazoles - pharmacology | Bacterial Proteins - antagonists & inhibitors | Cord Factors | Microbial Viability - drug effects | Bridged Bicyclo Compounds, Heterocyclic - chemistry | Antitubercular Agents - pharmacology | Rats | Genotype | Treatment Outcome | Mutation - genetics | Mycobacterium tuberculosis - isolation & purification | Spiro Compounds - pharmacokinetics | Hep G2 Cells | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Antitubercular Agents - pharmacokinetics | Dogs | Bacterial Proteins - metabolism | Mice | Kinetics | Spiro Compounds - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Mycobacterium tuberculosis - genetics | Pyrimidines | Tuberculosis | Genomics | Nucleotide sequencing | Drug therapy | Patient compliance | DNA sequencing | Trehalose | Medical treatment | Lung diseases | BCG | Cytotoxicity | Genomes | Drug resistance | Mutants | Gene sequencing | Chemistry | Lungs | Bacteria | Mutation | Piperidine
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 8, pp. 964 - 971
Background. Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes. Consequently, an effort to... 
artemisinin combination therapy | arterolane maleate | malaria | once-daily dose | fixed-dose combination | INFECTIOUS DISEASES | MULTICENTER | CLINICAL-TRIAL | EFFICACY | SAFETY EVALUATION | MICROBIOLOGY | IMMUNOLOGY | COMBINATION | CHILDREN | PHARMACOKINETICS | DIHYDROARTEMISININ-PIPERAQUINE | PLASMODIUM-FALCIPARUM | Africa - epidemiology | Peroxides - administration & dosage | Humans | Middle Aged | Fluorenes - therapeutic use | Half-Life | Spiro Compounds - administration & dosage | Male | Spiro Compounds - therapeutic use | Peroxides - therapeutic use | Plasmodium falciparum - drug effects | Quinolines - administration & dosage | Ethanolamines - administration & dosage | Heterocyclic Compounds, 1-Ring - administration & dosage | Young Adult | Malaria, Falciparum - epidemiology | Adult | Female | Fluorenes - administration & dosage | Drug Therapy, Combination | Child | Malaria, Falciparum - drug therapy | Double-Blind Method | Artemisinins - administration & dosage | India - epidemiology | Antimalarials - therapeutic use | Malaria, Falciparum - parasitology | Asia - epidemiology | Artemisinins - therapeutic use | Antimalarials - administration & dosage | Adolescent | Heterocyclic Compounds, 1-Ring - therapeutic use | Ethanolamines - therapeutic use | Aged | Quinolines - therapeutic use | Plasmodium falciparum | Youth | Adults | Teenagers | Research | Health aspects | and Commentaries
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2010, Volume 53, Issue 1, pp. 481 - 491
Journal Article
Science, ISSN 0036-8075, 5/2009, Volume 324, Issue 5928, pp. 801 - 804
New drugs are required to counter the tuberculosis (TB) pandemic. Here, we describe the synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new... 
Enzymes | Antibacterials | Tuberculosis | Mycobacterium tuberculosis | Cell walls | Antituberculars | Bacteria | Reports | Biochemistry | Enantiomers | Codons | IDENTIFICATION | MULTIDISCIPLINARY SCIENCES | CELL-WALL | Antitubercular Agents - chemical synthesis | Antitubercular Agents - chemistry | Thiazines - therapeutic use | Ethambutol - pharmacology | Drug Resistance, Bacterial | Molecular Sequence Data | Spiro Compounds - therapeutic use | Tuberculosis - microbiology | Mycobacterium tuberculosis - drug effects | Polysaccharides - biosynthesis | Microbial Sensitivity Tests | Racemases and Epimerases - metabolism | Enzyme Inhibitors - chemistry | Spiro Compounds - chemical synthesis | Tuberculosis - drug therapy | Arabinose - metabolism | Thiazines - pharmacology | Molecular Structure | Mycobacterium tuberculosis - metabolism | Spiro Compounds - chemistry | Antitubercular Agents - therapeutic use | Amino Acid Sequence | Genes, Bacterial | Antitubercular Agents - pharmacology | Enzyme Inhibitors - pharmacology | Racemases and Epimerases - antagonists & inhibitors | Enzyme Inhibitors - therapeutic use | Thiazines - chemical synthesis | Thiazines - chemistry | Mycobacterium - genetics | Mycobacterium - drug effects | Gene Expression Regulation, Bacterial - drug effects | Animals | Cell Wall - metabolism | Enzyme Inhibitors - cerebrospinal fluid | Mice | Mice, Inbred BALB C | Spiro Compounds - pharmacology | Mycobacterium tuberculosis - genetics | Antitubercular agents | Dosage and administration | Drug therapy | Genetics | Pharmacology | Chemical synthesis
Journal Article
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, ISSN 1042-7260, 06/2019, Volume 50, Issue 2, p. 470
Journal Article
Journal Article
Journal Article
Embo Molecular Medicine, ISSN 1757-4676, 2014, Volume 6, Issue 3, pp. 372 - 383
The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose... 
DprE1 | combination regimens | benzothiazinones | tuberculosis | Benzothiazinones | Tuberculosis | Combination regimens | MYCOBACTERIUM-TUBERCULOSIS | MEDICINE, RESEARCH & EXPERIMENTAL | IN-VITRO | PA-824 | GRANULOMA-FORMATION | BTZ043 | Antitubercular Agents - chemical synthesis | Thiazines - therapeutic use | Humans | Bacterial Proteins - chemistry | Crystallography, X-Ray | Spiro Compounds - therapeutic use | Piperazines - chemistry | Embryo, Nonmammalian - drug effects | Mycobacterium tuberculosis - drug effects | Tuberculosis - drug therapy | Thiazines - pharmacology | Lung - metabolism | Binding Sites | Spiro Compounds - chemistry | Antitubercular Agents - therapeutic use | Disease Models, Animal | Thiazines - pharmacokinetics | Catalytic Domain | Antitubercular Agents - pharmacology | Alcohol Oxidoreductases - metabolism | Piperazines - therapeutic use | Piperazines - pharmacology | Thiazines - chemistry | Zebrafish - growth & development | Molecular Dynamics Simulation | Spiro Compounds - pharmacokinetics | Hep G2 Cells | Animals | Spleen - metabolism | Alcohol Oxidoreductases - chemistry | Bacterial Proteins - metabolism | Mice | Spiro Compounds - pharmacology | Chronic diseases | Enzymes | Analysis | Sugars | Monosaccharides | Drugs | Animal models | Acquired immune deficiency syndrome--AIDS | Ribose | Piperazine | New combinations | Clinical trials | Pyrazinamide | Epimerase | Crystal structure
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2014, Volume 57, Issue 21, pp. 9078 - 9095
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 9/2012, Volume 55, Issue 5, pp. 663 - 671
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 04/2017, Volume 27, Issue 7, pp. 1551 - 1556
[Display omitted] Herein we report the synthesis of twelve 2,5-substituted 4-(trifluoromethyl)-spirochromeno[4,3-d]pyrimidines (7–10), as well as an evaluation... 
Arthritic pain | Analgesic effects | Trifluoromethyl | Spiro compounds | Chromeno[4,3-d]pyrimidines | DESIGN | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | PATHOLOGICAL PAIN | INDUCED ARTHRITIS | FLUORINE | AGENTS | MICE | PHARMACOLOGICAL EVALUATION | DERIVATIVES | NOCICEPTION | CAPSAICIN | Hyperalgesia - chemically induced | Arthritis - physiopathology | Benzopyrans - therapeutic use | Capsaicin | Pyrimidines - chemical synthesis | Ketoprofen - pharmacology | Spiro Compounds - administration & dosage | Spiro Compounds - therapeutic use | Heterocyclic Compounds, 3-Ring - chemical synthesis | Pain - chemically induced | Arthritis - chemically induced | Benzopyrans - chemical synthesis | Pain - drug therapy | Spiro Compounds - chemical synthesis | Nociception - drug effects | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Pyrimidines - administration & dosage | Ketoprofen - administration & dosage | Hyperalgesia - physiopathology | Benzopyrans - administration & dosage | Animals | Hyperalgesia - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Pain - physiopathology | Pyrimidines - therapeutic use | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Mice | Pyrimidines | Analysis | Index Medicus
Journal Article